Antiepileptic Drugs in Pediatrics.
Handb Exp Pharmacol
; 261: 1-24, 2020.
Article
en En
| MEDLINE
| ID: mdl-31342278
ABSTRACT
Epilepsy affects approximately 1% of the population. First-line treatment for epilepsy is the administration of anti-seizure medication, also referred to as antiepileptic drugs (AEDs), although this nomenclature is erroneous as these medications typically do not impact underlying epileptogenic processes; the goal of these medications is to control symptoms. Over 30% of patients are classified as having "medically refractory" epilepsy, i.e., lack of adequate seizure control despite trials of two or three AEDs (Kwan and Brodie, N Engl J Med 342314-9, 2000). Epilepsy is associated with worse quality of life in children, adolescents, and their families (Cianchetti et al., Seizure 2493-101, 2015). Patients with epilepsy have a two to three times greater risk of death than the general population, by various causes including sudden unexplained death in epilepsy patients (SUDEP) (Abdel-Mannan et al., Epilepsy Behav 9099-106, 2019). It is these factors, among others, that have motivated the continued development of AEDs. This chapter will review the history and evolution of AED development, features of specific AEDs with a focus on the newest generation, and examples of AEDs in development.
Palabras clave
Texto completo:
1
Banco de datos:
MEDLINE
Asunto principal:
Pediatría
/
Epilepsia
/
Anticonvulsivantes
Límite:
Adolescent
/
Child
/
Humans
Idioma:
En
Revista:
Handb Exp Pharmacol
Año:
2020
Tipo del documento:
Article
País de afiliación:
Estados Unidos